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ABSTRACT (250) 
 
Objective: Monogenic defects in the interleukin-10 (IL-10) pathway are extremely rare and 
cause infantile-onset inflammatory bowel disease (IBD)-like pathology. Understanding how 
immune responses are dysregulated in monogenic IBD-like diseases can provide valuable 
insight in “classical” IBD pathogenesis. Here, we studied long-term immune cell development 
and function in an adolescent IL-10 receptor (IL10RA)-deficient patient who presented in 
infancy with severe colitis and fistulizing perianal disease and is currently treated with 
immune suppressants. 
Methods: Biomaterial was collected from the IL10RA-deficient patient, pediatric IBD 
patients and healthy controls. The frequency and phenotype of immune cells were determined 
in peripheral blood and intestinal biopsies by flow cytometry and immunohistochemistry. 
Functional changes in monocyte-derived dendritic cells and T cells were assessed by in vitro 
activation assays. 
Results: The IL10RA-deficient immune system developed normally with respect to numbers 
and phenotype of circulating immune cells. Despite normal co-stimulatory molecule 
expression, bacterial lipopolysaccharide-stimulated monocyte-derived dendritic cells from the 
IL10RA-deficient patient released increased amounts of TNFα compared to healthy controls. 
Upon T-cell receptor ligation, IL10RA-deficient peripheral blood mononuclear cells released 
increased amounts of T cell cytokines IFN and IL-17 agreeing with high numbers of T-bet+ 
and IL-17+ cells in intestinal biopsies taken at disease onset. In vitro, the immunosuppressive 
drug thalidomide used to treat the patient decreased peripheral blood mononuclear cell-
derived TNFα production. 
Conclusions: With time and during immunosuppressive treatment the IL10RA- deficient 
immune system develops relatively normally. Upon activation, IL-10 is crucial for controlling 
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excessive inflammatory cytokine release by dendritic cells and preventing IFN and IL-17-
mediated T-cell responses.  
 
Keywords: Dendritic cell; T cell; Crohn’s disease; ulcerative colitis; interleukin-10 
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What is known 
o Monogenic defects in IL-10 and its receptor genes IL10RA and IL10RB cause 
infantile-onset IBD-like immunopathology with a severe phenotype that can only be 
treated with bone marrow transplantation. 
o Sequence variants in the IL-10 gene predispose to the development of “classical” IBD, 
particularly ulcerative colitis. 
o In mice, IL-10 orchestrates intestinal immune homeostasis by controlling innate and 
adaptive immune responses. 
o IL-10 is secreted in the late phase of cellular activation and has a significant inhibitory 
effect on inflammatory responses. 
 
What is new 
o The immune system has developed relatively normally in an adolescent IL10RA-
deficient patient receiving immunosuppressive therapy.  
o Cytokine secretion by stimulated human dendritic cells (TNFα) and T cells (IFN and 
IL-17) was elevated in the absence of a functional IL-10 pathway.    
o The immune patterns uncovered from patients with IL10RA deficiency can be useful 
for the identification of “classical” IBD patients with suboptimal IL-10 signaling. 
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INTRODUCTION  
Chronic inflammation of the gastrointestinal tract, as seen in inflammatory bowel disease 
(IBD), is driven by uncontrolled immune responses to commensal microbiota. Over the years, 
over 160 susceptibility loci have been identified for classical IBD, some of which have led to 
the identification of gene polymorphisms that contribute to disease pathogenesis (1, 2). In 
addition, more than 50 monogenic defects have been identified in children with early-onset 
(before the age of 10 years) IBD-like gastrointestinal pathology classified as the A1a group in 
the Paris classification for pediatric-onset IBD (3-5). As many of these monogenic defects fall 
within inflammatory immune networks that are shared by genetic variants conferring 
susceptibility to classical IBD, detailed analysis of patients with monogenic disorders may 
yield immune patterns that are useful to categorize classical IBD.  
One of the key genes that clusters within the IBD susceptibility loci and monogenic disorders 
encodes interleukin-10 (IL-10) (3), a potent immunoregulatory cytokine essential for 
mounting tolerance to harmless intestinal microbial antigens. In the intestine, IL-10 is mainly 
produced by myeloid cells including macrophages and dendritic cells, as well as regulatory T 
cells and B cells (6). Once secreted, IL-10 exerts its biological effects via a heterodimeric 
receptor complex composed of two IL-10 binding chains (IL-10RA) and two accessory chains 
(IL-10RB), the latter being shared with other receptors of IL-10 cytokine family members (7). 
The polymorphisms in the IL-10 pathway associated with IBD (8-11) and the discovery of 
IL10 and IL10R loss-of-function mutations causing severe, infantile-onset IBD (12-15) reveal 
the importance of the IL-10 pathway in maintaining intestinal immune homeostasis. However, 
identifying the mechanisms by which IL-10 exerts suppression has been challenging. 
With the aid of animal models, IL-10 has been recognized as a major regulator of 
intestinal innate and adaptive immune responses. Mice deficient in IL-10 or IL-10 receptor 
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develop intestinal inflammation, which is dependent on bacterial colonization (16, 17). Recent 
animal studies have demonstrated that IL-10 sensing by innate immune cells comprising 
macrophages and dendritic cells (DCs) is required for maintenance of intestinal homeostasis 
(18-20). Regarding adaptive immune responses, defective IL-10 receptor signaling in 
memory/effector T cells renders these cells more colitogenic than wild-type cells in a mouse 
model of transfer colitis (21). Although it is now widely appreciated that IL-10 orchestrates 
intestinal homeostasis, the precise immune cell dysfunctions resulting from a defective IL-10 
pathway and their role in driving intestinal inflammation in human are only beginning to be 
uncovered. So far, only alterations in human macrophage differentiation and function have 
been described in patients with a defective IL-10 pathway (19, 22). Functional studies in 
human are limited because IL10 and IL10R-deficient patients are extremely rare, with most 
having undergone a hematopoietic stem cell transplantation shortly after diagnosis. As genetic 
screening has become more accessible, it is expected that a substantial number of now 
adolescent IBD patients who suffered from early-onset IBD will be diagnosed with a 
monogenic disorder. A young age of presentation and progressive disease severity can be 
reasons for  genetic screening to detect monogenic defects that are associated with IBD-like 
pathology in adolescent patients (23). Studying such adolescent patients may prove a valuable 
addition to identify the long-term consequences of a particular defect on immune 
development. Here, we studied an adolescent IL10RA-deficient patient currently treated with 
immune suppressants who presented with infantile IBD and was diagnosed with IL10RA 
deficiency at the age of 9 years. The aim of this study was to determine the effects of an 
inherited defect in the IL-10 pathway on both the development and function of innate and 
adaptive immune cells.  
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METHODS  
Patients  
Blood was collected in EDTA tubes from an IL10RA-deficient patient, cohorts of pediatric 
IBD patients, age-matched healthy orthopedic patients without underlying inflammatory or 
intestinal disease (Table 1) and adult healthy laboratory volunteers (age between 22-62 
years). All IBD patients had clinical characteristics and were diagnosed by endoscopy and 
histology of multiple biopsies according to the Porto criteria (24). All participants and/or their 
parents gave written informed consent and the study was approved by the local ethics 
committee.  
 
At the age of 9 years, an IBD patient with infantile disease onset and from  a consanguineous 
Turkish family was diagnosed with IL10RA deficiency through homozygosity mapping. 
Briefly, leukocyte DNA was hybridized to an Affymetrix GeneChip 260k Nsp1 SNP array 
(Santa Clara, CA, USA). Regions of homozygosity were identified in the patient and her 
unaffected sister using CNAG software (version 3)(25) The exons and flanking intron regions 
of IL10RA were sequenced after PCR amplification. A single nucleotide deletion resulting in 
a frame-shift and premature stop codon (c.585delT, p.Gly196Glufs*10) was identified 
(Figure 1b, c) and confirmed in an accredited diagnostic laboratory using an ABI 3730 DNA 
Analyzer and SeqPatient genetic analysis software (JSI Medical Systems). NM_001558.3 was 
used as a reference sequence. A similar mutation was found in her deceased brother 
(confirmation on DNA isolated from paraffin embedded intestinal biopsy). IL10RA deficiency 
was confirmed by immunohistochemistry in colonic biopsy specimens previously taken from 
the patient at time of diagnosis (Figure 1d), and functional assays on patients' peripheral 
blood mononuclear cells (Figure 1e, f). 
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The currently 13-year-old female with an IL10RA deficiency presented like other patients 
with mutations in the IL-10 pathway with abscesses and fissures in the perianal region in the 
first months of life (15, 26). A male sibling, who had also presented with perianal disease and 
severe gastrointestinal symptoms, died at the age of 18 months due to a bowel perforation 
after colonoscopy. Colonoscopy at the age of 2 months in the female patient showed mild left-
sided colitis with normal crypt differentiation and mild focal inflammation with inflammatory 
cell infiltration in the crypt epithelium in mucosal biopsies. At the age of 10 months, colonic 
inflammation was more severe with tissue ulceration and abundant mononuclear and 
polymorphonuclear cell infiltration in the epithelium and lamina propria (Supplemental 
Digital Content, Fig., http://links.lww.com/MPG/A927). The patient failed to achieve full 
clinical remission during treatment with exclusive elemental nutrition, antibiotics, 
sulfasalazine, prednisone, infliximab, and methotrexate. Colchicine was started because of 
suspicion of Behcet’s disease at the age of 2 years. The patient's medical record timeline is 
shown in Figure 1a. Until now, the family has refused hematopoietic stem cell 
transplantation, because of the risk of the procedure in relation to the relatively mild clinical 
course. Currently, she has only occasionally had clinically mild gastrointestinal symptoms 
since the age of three while receiving thalidomide and intravenous immunoglobulin. Fecal 
calprotectin is only mildly elevated (151 microgram/g, normal values in IBD patients <100 
microgram/g). Respiratory infections, that were severe from age 2 years, have decreased since 
the start of monthly intravenous immunoglobulins, as advised by the 
immunology/infectiology team. Between the ages 9 until 13 blood was repeatedly collected 
from the IL10RA-deficient patient before her monthly intravenous immunoglobulins infusion. 
At the time of the experiments the patient had no physical complaints. 
Flow Cytometry 
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Whole blood samples were lysed and stained with antibodies directed against CD11c (B-ly6), 
HLA-DR (L243), CD3 (HIT3), CD4 (RPA-T4), CD8 (SK-1), CD38 (HIT2), CD62L (DREG-
56), CD40 (5C3), CD80 (2D10), CD86 (2331), HLA-DR (L243), (all purchased from BD 
Biosciences (San Jose, CA, USA), eBioscience (San Diego, CA, USA) or Biolegend (San 
Diego, CA, USA)) and CCR9 (R&D Systems, Minneapolis, MN, USA). For intracellular 
cytokine staining, peripheral blood mononuclear cells were stimulated for 4h with phorbol 12-
myristate 13-acetate (0.05 μg/ml, Sigma-Aldrich, St. Louis, MO USA) and ionomycin (0.5 
μg/ml, Sigma-Aldrich) in the presence of Brefeldin A (3 μg/ml eBioscience) for the last 3h. 
Cells were stained with anti-CD3 (BD biosciences), fixed in 2% formaldehyde, permeabilized 
with saponin (Sigma-Aldrich), and labeled with anti-IL-21 (eBio3A3-N2; eBioscience), anti-
IL-17A (eBio64DEC17; eBioscience), anti-IFN (4SB3, BD biosciences), or appropriate 
isotype controls (eBioscience). Foxp3 was stained using the Foxp3 Staining Buffer Set 
(eBioscience) according to manufacturer’s protocol. Cells were analyzed using the 
FACSCanto II (BD Biosciences) and FlowJo software.  
 
Cell isolation and Culture 
Cells were cultured in Iscove’s modified Dulbecco’s medium (Lifetechnologies, Grand 
Island, NY, USA) supplemented with heat inactivated fetal calf serum, Glutamax 
(Lifetechnologies), 2-mercaptoethanol, penicillin and streptomycin. Peripheral blood 
mononuclear cells were isolated using a Ficoll-Hypaque gradient and stimulated with purified 
lipopolysaccharide from Escherichia coli Serotype 0111:B4 (100 ng/ml, Sigma-Aldrich) or 
anti-CD3 (500 ng/ml; Sanquin, the Netherlands) with or without IL-10 (25 ng/ml, R&D 
Systems) or thalidomide (1, 10 µg/ml, Celgene Corp.) for the indicated time-points. CD14+ 
monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, 
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Germany) according to the manufacturer’s instructions. Purified monocytes (>90%) were 
differentiated into monocyte-derived dendritic cells (moDCs) during a 6-day culture with 800 
U/ml GM-CSF (Novartis, Basel, Switzerland) and 400 U/ml IL-4 (R&D). At day 6, LPS was 
added to the wells in the presence or absence of IL-10. Supernatants were collected at day 7.  
 
Measurement of Cytokines in Cell Culture Supernatant 
Cytokine production was measured in cell culture supernatants using enzyme-linked 
immunosorbent assays for TNFα (BD biosciences, Breda, the Netherlands), IFN 
(eBiosciences) or IL-17A (Duoset; R&D Systems) or by application of the standard protocol 
of the Human Inflammation Cytometric Bead Array specific for IL-8, IL-1β, IL-6, IL-10, 
TNF, IL-12p70 (BD Biosciences).  
 
Immunohistochemistry on Paraffin Sections 
Paraffin embedded biopsies were sectioned, deparaffinized, and endogenous peroxidase 
activity was quenched with 3% H2O2 in PBS for 20 min. Antigen retrieval was performed by 
microwave treatment in citrate buffer (10 mM, pH 6.0) or enzymatic treatment with 0.1% 
pepsin. The sections were blocked for 1h in 10% normal human serum plus 10% normal goat, 
rabbit or horse serum diluted in 10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 
0.05% Tween-20, pH 8. Antibody incubation was performed overnight at 4°C using anti-IL-
10RA (polyclonal rabbit, Millipore, Temecula, CA, USA), anti-CD3 (polyclonal rabbit, 
DakoCytomation, Glostrup, Denmark), anti-IL-17A (polyclonal goat IgG; R&D Systems, 
Abingdon, UK), anti-IL-21 (polyclonal rabbit IgG, Lifespan Biosciences, Seattle, WA, USA), 
anti-Foxp3 (mouse IgG1 clone 236A/E7, eBiosciences, San Diego, CA, USA), anti-T-bet 
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(mouse IgG clone 4Bio, eBiosciences), or proper isotype control antibodies. Immunoreactive 
sites were detected with biotinylated secondary antibodies using the Vectastain ABC Elite Kit 
(Vector Laboratories, Burlingame, CA, USA) and 3,3’-diaminobenzidine tetrahydrochloride 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Tissues were counterstained with 
hematoxylin (Vector Laboratories). Images were acquired using a Leica DM5500B upright 
microscope and LAS image acquisition software (Leica Microsystems, Rijswijk, The 
Netherlands). 
 
Statistical Analysis   
Significance was determined using Student’s t-test or Mann–Whitney U-test performed on 
GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA). P-values of <0.05 were 
regarded as significant.  
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RESULTS  
 
Normal distribution of circulating dendritic cells and T cell subsets in the IL10RA-
deficient patient during treatment 
Primary immunodeficiency caused by monogenic defects often leads to abnormal immune 
cell development, cellular dysfunction, or both. To determine whether an inherited defect in 
the IL-10 pathway causes abnormal immune cell development, we determined the frequency 
of the major circulating immune cell populations in the IL10RA-deficient patient during 
adolescence. While in remission, the percentages of circulating CD11c+HLA-DR+ dendritic 
cells (Figure 2a), CD4+ and CD8+ T cells (Figure 2b) of the patient were within the normal 
range for pediatric IBD patients (in remission or with active disease) and age-matched 
orthopedic patients. Similarly, the frequency of Foxp3+ cells within the CD4+ T cell 
population was comparable between the IL10RA-deficient patient and pediatric IBD patients 
and pediatric controls (Figure 2c). To investigate changes in circulating mucosal CD4+ T 
cells in particular, we analyzed the combined cell-surface expression of CD62Lneg and CD38 
as well as the gut-homing marker CCR9 within the CD4+ T cell population (27, 28). Both the 
percentages of circulating CD4+CD62LnegCD38+ cells and gut-homing CD4+CCR9+ cells 
were not different to pediatric controls or pediatric IBD patients (Figure 2d). Moreover, no 
differences were observed for CD4+CD62LnegCD38neg cells, CD4+CD62L+CD38neg cells, and 
CD4+CD62L+CD38+ cells (data not shown).  Consistent with the unchanged T-cell 
frequencies, the percentages of CD3+ T-cell subpopulations producing the effector cytokines 
IL-17, IFN and IL-21 were comparable to pediatric IBD patients in remission (Figure 2e). 
Thus, in the absence of a functional IL-10 pathway, during treatment with thalidomide, 
colchicine, and intravenous immunoglobulins the immune system has developed with normal 
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frequencies of CD11c+HLA-DR+ DCs and circulating effector memory T cell subsets.  
 
Functional consequences of defective IL-10 signaling on monocyte-derived dendritic 
cells  
The functional impact of primary immunodeficiency on innate and adaptive immunity helps 
to elucidate underlying mechanisms of disease. Recent evidence from animal studies 
demonstrates that loss of IL-10R expression by innate immune cells causes severe colitis (18-
20). Therefore, we investigated whether alterations in the in vitro generation and function of 
DCs, as part of the innate immune system, occur in the absence of a functional IL-10 
pathway. Monocytes from the IL10RA-deficient patient differentiated normally into DCs in 
response to GM-CSF and IL-4. As expected (29), LPS-induced upregulation of co-stimulatory 
molecules was inhibited by exogenous IL-10 in healthy control moDCs, but not in IL10RA-
deficient moDCs. Post stimulation, expression levels of HLA-DR and the co-stimulatory 
molecules CD40, CD80, and CD86 were comparable between the IL10RA-deficient moDCs 
and healthy control moDCs (Figure 3a). In contrast, significantly higher amounts of TNFα 
were released by LPS-stimulated IL10RA-deficient moDCs, while IL-10 production was 
similar to healthy control moDCs (Figure 3b). Comparable to that observed for TNFα, 
IL10RA-deficient moDCs released higher amounts of the chemotactic cytokine CXCL-8 in 
response to LPS (data not shown). These data demonstrate that IL10RA-deficient moDCs 
develop normally and do not hyper-express co-stimulatory molecules, but when stimulated 
with LPS, these cells secrete significantly more pro-inflammatory cytokines. 
IL-10 fails to suppress effector T-cell responses in the IL10RA-deficient patient 
Considering that DCs are potent inducers of primary T-cell immune responses and that IBD is 
mediated by abnormally activated effector T cells predominantly secreting IFN and IL-17 
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(30), we next investigated whether the IL10RA-deficient patient exhibits alterations in effector 
T-cell responses. IL-10 inhibited secretion of the effector T cell cytokines IFN and IL-17 by 
anti-CD3-stimulated peripheral blood mononuclear cells from healthy controls (Figure 3c). 
Interestingly, upon anti-CD3 stimulation, peripheral blood mononuclear cells from the 
IL10RA-deficient patient secreted significantly enhanced amounts of IFN, and to a lesser 
extent IL-17, which could not be inhibited by exogenous IL-10 (Figure 3c). To ascertain 
whether these effector T cell cytokines or the transcription factor critical for their production 
had possibly played a role in patients’ colitis, we performed immunohistochemical analysis of 
paraffin-embedded biopsies obtained from the IL10RA-deficient patient at disease onset. At 
the age of 2 and 10 months, descending colon tissue showed an influx of lamina propria and 
intra-epithelial CD3+ cells (Figure 4a-c). Co-staining of serial sections revealed that the 
majority of the CD3+ cells co-localized with IL-21+, IL-17A+, and/or T-bet+ cells in the 
inflamed mucosa (Figure 4c). For comparison, descending colon tissue of an age-matched (5 
months old) non-IBD patient suffering from cow's milk protein intolerance is shown (Figure 
4d). Foci of Foxp3+ cells were detected in the intestinal mucosa lesions, suggesting that the 
intestinal inflammation is not simply a consequence of defective Foxp3+ T cell recruitment. In 
conclusion, these data demonstrate that IL-10 is essential for suppressing IFN and IL-17-
secreting effector T cells, and that in the absence of a functional IL-10 pathway, inflammatory 
lesions in the colon contain both effector T cell subsets. 
 
Thalidomide inhibits LPS-mediated TNF production but not anti-CD3-driven IFN 
and IL-17 production by peripheral blood mononuclear cells 
Given that IL-10R signaling is crucial for controlling the function of moDCs and cytokine 
secretion by effector T cells, we next addressed the effect of the patient’s current therapy on 
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both innate and adaptive immune responses in vitro. Since treatment with thalidomide 
primarily promoted clinical remission of the intestinal symptoms in the IL10RA-deficient 
patient, we developed an in vitro assay system in which we studied the effects of thalidomide 
on innate and adaptive immune responses to bacterial LPS and T-cell receptor ligation, 
respectively. Thalidomide treatment had no significant effect on anti-CD3-mediated IFN and 
IL-17 cytokine secretion by peripheral blood mononuclear cells from healthy controls (Figure 
5a, c) and the IL10RA-deficient patient (Figure 5b, d). However, thalidomide significantly 
decreased TNFα production by LPS-stimulated peripheral blood mononuclear cells from both 
healthy controls (Figure 5e) and the IL10RA-deficient patient (Figure 5f). PBMC from the 
IL10RA-deficient patient seemed less sensitive to the effects of thalidomide, possibly because 
the cells have already been exposed to this drug in the patient. Altogether, these results 
suggest that inhibition of innate responses may contribute to disease suppression. 
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DISCUSSION  
We investigated the long-term impact of a defective IL-10 pathway on immune system 
development and function in an adolescent patient with an IL10RA loss-of-function mutation 
who presented with severe early-onset IBD within the first year of life. In the absence of a 
functional IL-10 pathway, we observed no alterations in the composition of major immune 
cell populations in the blood. Yet, we demonstrate that upon stimulation, IL-10 is crucial for 
controlling excessive inflammatory cytokine release by moDCs and for optimal suppression 
of T-cell responses. These findings identify DCs and T cells as essential targets of IL-10 
action in controlling cell-mediated immune responses in human.  
During treatment, the number of circulating CD11c+ DCs was normal in the IL10RA-
deficient patient, indicating sufficient bone marrow output and differentiation of the myeloid 
cell lineage. DCs generated in vitro from peripheral blood monocytes showed normal 
upregulation of MHCII and co-stimulatory molecules but when stimulated with a bacterial 
stimulus, IL10RA-deficient moDCs secreted significantly higher amounts of TNFα. The in 
vitro generation of functional DCs occurred independently from any confounding effects of 
ongoing intestinal inflammation or drug therapy, suggesting a cell-intrinsic effect of IL10R 
deficiency on pro-inflammatory cytokine production by these cells. The differential regulation 
of co-stimulatory molecule expression and cytokine production is notable, as previous 
neutralization studies proposed a role for IL-10 in both autocrine co-stimulation and cytokine 
release (31, 32). However, our data are in line with observations in CD11c+-specific Il10r-
deficient mice, in which only cytokine release and not co-stimulatory molecule expression by 
CD11c+ cells was affected (33). In our study, cytokine production by cells of the IL10R-
deficient patient were compared to those from adult healthy volunteers. Cytokine production 
may differ between children and adults. However, it has been shown that in healthy children, 
cytokine production by PBMC is lower compared to adults upon mitogen and antigen 
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stimulation (34). Therefore, the degree with which the cytokine production by cells from the 
IL10RA-deficient patient is enhanced may be an underestimation.  
Similar as observed for DCs, the composition of T-cell subpopulations in peripheral 
blood did not differ between the IL10RA-deficient patient and pediatric controls and pediatric 
IBD patients. This is of interest as IL-10 has been proposed to act as a cofactor for thymocyte 
proliferation (35). Consistent with prior findings (36), exogenous IL-10 inhibited IFNand 
IL-17 secretion by in vitro-activated peripheral blood mononuclear cells from control 
subjects. Reciprocally, in the IL10RA-deficient patient an enhancement in IFNT-bet and 
IL-17 expression was seen in mucosal tissue and peripheral blood mononuclear cells. In mice, 
T helper 17 (Th17) cells, but not IFN-producing T helper type 1 (Th1) cells, express a 
functional IL-10 receptor and are sensitive to the IL-10 inhibitory effects (37). Besides a 
direct effect, IL-10 signaling in regulatory T cells has also been implicated in limiting 
pathogenic Th17 cell responses (38). Moreover, several groups have demonstrated that 
especially IL-10 sensing by innate immune cells is required for suppression of T cell-driven 
intestinal inflammation (18-20). Whether IL-10 regulates human IFNand IL-17-secreting 
T cells directly or indirectly via innate immune cells or by favoring Treg cell-mediated 
suppression awaits further studies. 
The observed inhibitory effect of thalidomide on TNFα production by LPS-stimulated 
IL10RA-deficient peripheral blood mononuclear cells suggests that the inhibition of TNFα 
secretion contributes to suppression of innate responses and may be involved in the clinical 
remission of the intestinal symptoms. However, as the patient failed to respond to infliximab, 
mechanisms other than TNFα inhibition may have contributed to disease control. Thalidomide 
is known to inhibit NF-κB activity (39) as well as activation of caspase-1 and thereby 
secretion of biologically active IL-1β protein (40). As thalidomide suppresses IL-12 
production by human monocytes (41), it is tempting to speculate that thalidomide may be 
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effective in inhibiting Th1 cytokine responses. Moreover, thalidomide binds cereblon, an 
upstream regulator of interferon regulatory factor (IRF)4 (42, 43). IRF4 is an important 
regulator of TH17 cells, and Irf4-deficient mice display reduced Il17 gene expression during 
chronic intestinal inflammation (44). Although thalidomide had no effect on IFN and IL-17 
production in vitro, we cannot exclude an effect of thalidomide on T cells in vivo.  
The abnormalities caused by monogenic defects in IBD-like disease hold valuable 
knowledge on the mechanisms that may predispose to “classical” IBD. Our findings show that 
IL10R deficiency has a major impact on the cytokine secretion by human moDCs (TNFα) and 
T cell cytokine production (IFN and IL-17), suggesting that these defects may contribute to 
the clinical manifestation of the IBD-like gastrointestinal pathology. Although the primary 
limitation of this study is that it involves only one IL10RA-deficient patient, we expect similar 
results in other patients with defects in the IL-10 pathway. Besides moDCs and T cells, it has 
been recently reported that monocyte-derived macrophages from IL10R-deficient patients 
secrete significantly more pro-inflammatory cytokines (19). Interestingly, the biological 
process term ‘regulation of cytokine production’ is significantly enriched among the 163 IBD 
susceptibility loci, and further detailed analysis showed an enrichment for genes expressed 
especially by DCs and to a lesser degree CD4+ T cells (2). These and our findings underscore 
the importance of aberrant activated innate immune cells and CD4+ T cells in inflammatory 
bowel disease pathology. The identified immune abnormalities in monogenic disease may be 
useful for the functional understanding and classification of polygenic classical IBD 
phenotypes. It can be envisaged that a subgroup of IBD patients may exhibit milder forms of 
IL-10 deregulation. Future studies will focus on the immunological alterations in IL10R-
deficient patients and uncover biomarkers and immune assays to identify individuals with 
suboptimal IL-10 signaling among polygenic classical IBD patients.  
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Collectively, our data provide fundamental insights into the immune system 
development and functions in an IL10R-deficient patient. Our findings promote our 
knowledge of intestinal immune regulation, which is required to advance our ability to 
classify the varying clinical pathologies of IBD.  
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FIGURE LEGENDS  
Figure 1. Functional analysis of the IL10RA mutation. 
(a) The IL10RA-deficient patient's medical record timeline (b) Sequencing of the IL10RA region 
revealed a homozygous single nucleotide deletion (c.585delT, p.Gly196Glufs*10) in exon 5 
resulting in a frame-shift and premature stop codon. (c) Intron-exon organization of the full-
length and mutated IL10RA gene. The premature stop codon predicts a truncated receptor lacking 
the transmembrane and intracellular regions. Exons are shown in boxes, introns as lines, and 
mRNA as thick lines. (d) Immunohistochemical detection of IL-10R in paraffin-embedded colon 
descendens sections from the IL10RA-deficient patient and a pediatric IBD patient using an 
antibody raised against the cytoplasmic domain of human IL-10RA (residues 257-278). (e) 
Control or patient whole blood was stimulated with IL-10 (25 ng/ml) for 15 min or IL-6 (100 
ng/ml) for 30 min, and STAT3 phosphorylation (Tyr705) was quantified by flow cytometry. 
Gated on monocytes for IL-10 stimulation or the whole cell population for IL-6 stimulation. (f) 
Control and patient peripheral blood mononuclear cells were stimulated with LPS (100 ng/ml) in 
the absence or presence of IL-10 (25 ng/ml). After 6h, supernatants were collected and TNFα 
secretion was measured by ELISA. *P<0.05.  
 
 
  
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
  28
Figure 2. Similar numbers of circulating CD11c+HLA-DR+ dendritic cells and T cell 
populations in the IL10RA-deficient patient and pediatric controls  
Flow cytometric analysis for CD11c, HLA-DR, CD4, CD8, CD62L, CD38, CCR9, and/or Foxp3 
was performed on peripheral blood from pediatric IBD patients, pediatric controls and the 
IL10RA-deficient patient (a) Frequency of the CD11c+HLA-DR+ dendritic cell population (b) 
Frequencies of CD4+ and CD8+ T lymphocytes. (c) Frequency of Foxp3+ cells gated on CD4+ 
lymphocytes. (d) Frequencies of CD62LnegCD38+ and CCR9+ cells gated on CD4+ lymphocytes. 
(e) Peripheral blood mononuclear cells were stimulated for 4h in vitro and stained for 
intracellular IFN, IL-21, IL-17A, and appropriate isotype controls followed by flow cytometry 
analysis. Representative cytokine dot plots for the IL10RA-deficient patient are shown; the 
numbers below the dot plots indicate the ranges of cytokine expression in five pediatric IBD 
patients in remission.  
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Figure 3. IL-10 controls excessive inflammatory cytokine release by dendritic cells and T 
cells 
(a) Adult healthy control and patient monocyte-derived dendritic cells were matured with LPS 
(100 ng/ml) in the presence or absence of IL-10 (25 ng/ml). After 20h, cells were analyzed by 
flow cytometry for expression of CD40, CD80, CD86, and HLA-DR. Mean fluorescence 
intensity values (MFI) for all conditions are shown below histograms. Data shown are from one 
of three representative experiments. (b) Amount of TNFα secreted by monocyte-derived 
dendritic cells as determined by cytometric bead array. IL-10 was measured in supernatants 
using cells from five adult healthy controls and supernatants from five replicate cultures with 
cells from the IL10RA-deficient patient (c) Adult healthy control and patient peripheral blood 
mononuclear cells were stimulated with anti-CD3 (500 ng/ml) in the absence or presence of IL-
10 (25 ng/ml). After 48h, supernatants were assayed for IFN and IL-17A using an ELISA. Data 
are mean ± SD of one of four representative experiments; *P<0.05. 
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Figure 4. Presence of CD3+, IL-21+, IL-17+, T-bet+ and Foxp3+ cells in the inflamed 
intestinal mucosa of the IL10RA-deficient patient  
Representative immunohistochemical staining for CD3, IL-21, IL-17A, T-bet, and Foxp3 in 
serial sections of paraffin-embedded biopsies of the colon descendens from the IL10RA-deficient 
patient taken at (a) 2 months and (b,c) 10 months (d) age-matched (5 months old) non-IBD 
patient suffering from cow’s milk protein intolerance. Polyclonal rabbit anti-goat Ig isotype 
control staining for IL-21 and CD3, goat IgG1 isotype control staining for IL-17A, mouse IgG1 
isotype control staining for Foxp3, and mouse IgG1 isotype control staining for T-bet are shown 
in the small inserts in the top panel. Original magnification x20.  
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Figure 5. Thalidomide inhibits LPS-mediated TNFα release, but not the anti-CD3-driven 
IFN and IL-17 release  
(a-d) Peripheral blood mononuclear cells were stimulated with anti-CD3 (500 ng/ml) in the 
presence of thalidomide (1 or 10 μg/ml) or DMSO control (1 or 10 μg/ml). After 48h, cytokine 
levels in culture supernatants were measured by ELISA. IL-17 and IFN response for (a, c) 
healthy adult donors and (b, d) the IL10RA-deficient patient are shown. The relative difference 
was calculated considering the percent of cytokine secretion upon anti-CD3 stimulation as 100%. 
(e,f) Peripheral blood mononuclear cells were stimulated with LPS (100 ng/ml) in the presence 
of thalidomide (1 or 10 μg/ml) or DMSO control (1 or 10 μg/ml). After 24h, cytokine levels were 
measured in the supernatant. TNFα response for (e) healthy adult donors and (f) the IL10RA-
deficient patient are shown. The relative difference was calculated considering the percent of 
cytokine secretion upon LPS stimulation as 100%. Data are mean ± SD of one of three 
representative experiments; *P<0.05 
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